	Application No.	Applicant(s)
Notice of Allowability	1200	
	10/019,661 Examiner	ZHANG ET AL. Art Unit
· · · · · · · · · · · · · · · · · · ·	Anne R. Kubelik	1638
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>response and amendment of 1/23/07</u> .		
2. The allowed claim(s) is/are <u>1,3-5,7,9-13 and 26</u> .		
 3.		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) 🔲 including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) In hereto or 2) In to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)	• -	
1. Notice of References Cited (PTO-892)	5. Notice of Informal P	• •
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☑ Interview Summary Paper No./Mail Dat	
Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date	7. 🛛 Examiner's Amendr	nent/Comment
4. Examiner's Comment Regarding Requirement for Deposit	8. 🗌 Examiner's Stateme	ent of Reasons for Allowance
of Biological Material	9.	
		·
		•
•		

Application/Control Number: 10/019,661 Page 2

Art Unit: 1638

Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR
 To ensure consideration of such an amendment, it MUST be submitted no later than the

payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with

Hyunkweon Ryu on 16 February 2007.

IN THE CLAIMS:

Claim 1 (Currently Amended). An isolated nucleic acid molecule encoding a bacterial

autoinducer inactivation protein, wherein the nucleic acid is selected from the group consisting

of:

a) the a nucleic acid of SEQ ID NO:1 having the sequence of the bases that

encode SEQ ID NO: 2; and

b) a nucleic acid encoding the amino acid sequence of SEQ ID NO:2

Claim 7 (Currently Amended). A method for increasing disease resistance in a plant or

animal, which method comprises introducing into a cell of such said plant or animal a nucleic

acid encoding a bacterial autoinducer inactivation protein, wherein the nucleic acid is selected

from the group consisting of:

a) the a nucleic acid of SEQ ID NO:1 having the sequence of the bases that

encode SEQ ID NO: 2; and

b) a nucleic acid encoding the amino acid sequence of SEQ ID NO:2.

Claim 26 (Currently Amended) A method of reducing bacterial autoinducer activity in a plant or animal, which method comprises introducing into a cell of such said plant or animal a the nucleic acid molecule encoding a bacterial autoinducer inactivation protein of claim 1.

Any inquiry concerning this communication or earlier communications from the 2. examiner should be directed to Anne R. Kubelik, whose telephone number is (571) 272-0801. The examiner can normally be reached Monday through Friday, 8:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg, can be reached at (571) 272-0975.

The central fax number for official correspondence is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Anne R. Kubelik, Ph.D. February 16, 2007

> NNE KUBELIK, PH.D. PRIMARY EXAMINER

Page 3